OCS OCULIS HOLDING AG

Oculis to Present at Upcoming May Investor Conferences

Oculis to Present at Upcoming May Investor Conferences

ZUG, Switzerland, May 07, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced that Oculis will be attending and presenting at the following upcoming investor conferences:

Bio€quity Europe

May 12-14, 2025; Bruges, Belgium

Company update by Riad Sherif, MD, Chief Executive Officer, on May 14 at 11am CET

Bank of America Healthcare Conference

May 13-15, 2025; Las Vegas, USA

Fireside chat with Sylvia Cheung, Chief Financial Officer, on May 14 at 3pm PT

H.C. Wainwright Annual BioConnect at Nasdaq

May 20, 2025; New York, USA

Company update by Sylvia Cheung, Chief Financial Officer, on May 20 at 9:30am ET

Stifel Virtual Ophthalmology Forum

May 27, 2025; Virtual

Fireside chat with Sylvia Cheung, Chief Financial Officer, on May 27 at 1pm ET

The Company will be available for one-on-one meetings during the conferences. Interested investors should contact their respective representative at the sponsoring institutions to request meetings.

Webcast links, when available, will be posted to the Oculis website on the  page under the Investors & Media section.

About Oculis

Oculis is a global biopharmaceutical company (Nasdaq: OCS; XICE: OCS) focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs. Oculis’ highly differentiated pipeline of multiple innovative product candidates in development includes: OCS-01, a topical eye drop candidate for diabetic macular edema (DME); Privosegtor (OCS-05), a neuroprotective candidate for acute optic neuritis with potentially broad clinical applications in other neuro-ophthalmic diseases and Licaminlimab (OCS-02), a topical biologic anti-TNFα eye drop candidate for dry eye disease (DED). Headquartered in Switzerland with operations in the U.S. and Iceland, Oculis is led by an experienced management team with a successful track record and supported by leading international healthcare investors.

For more information, please visit:

Oculis Contacts

Ms. Sylvia Cheung, CFO

Investor Relations

LifeSci Advisors

Corey Davis, Ph.D.

Media Relations

ICR Healthcare

Amber Fennell / David Daley / Sean Leous



EN
07/05/2025

Underlying

OCSOCULIS HOLDING AG

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on OCULIS HOLDING AG

 PRESS RELEASE
Free
OCS OCULIS HOLDING ...

Oculis Publishes Notifications of Transactions by Persons Discharging ...

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities and Persons Closely Associated ZUG, Switzerland, Feb. 18, 2026 (GLOBE NEWSWIRE) -- The attached notifications relate to the vesting of earnout shares and associated removal of restrictions on these ordinary shares. Attachments

21h / 36m 1 EN
 PRESS RELEASE
Free
OCS OCULIS HOLDING ...

Oculis Appoints Katie Kazem as Chief Legal Officer

Oculis Appoints Katie Kazem as Chief Legal Officer ZUG, Switzerland, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Ms. Kazem brings extensive and global expertise in corporate governance and securities law, drawing on a distinguished track record as external legal counsel to leading life sciences companiesChief Legal Officer (CLO) appointment enhances leadership capabilities to advance three highly differentiated late-stage assets toward near-term clinical and regulatory milestones Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough inno...

February 17, 2026 1 EN
 PRESS RELEASE
Free
OCS OCULIS HOLDING ...

Oculis Appoints Katie Kazem as Chief Legal Officer

Oculis Appoints Katie Kazem as Chief Legal Officer Ms. Kazem brings extensive and global expertise in corporate governance and securities law, drawing on a distinguished track record as external legal counsel to leading life sciences companiesChief Legal Officer (CLO) appointment enhances leadership capabilities to advance three highly differentiated late-stage assets toward near-term clinical and regulatory milestones ZUG, Switzerland, February 17, 2026 -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations to addr...

February 17, 2026 1 EN
 PRESS RELEASE
Free
OCS OCULIS HOLDING ...

Oculis to Showcase Transformative Late-stage Pipeline in Neuro-ophthal...

Oculis to Showcase Transformative Late-stage Pipeline in Neuro-ophthalmology and Ophthalmology at the 2026 J.P. Morgan Healthcare Conference ZUG, Switzerland, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Breakthrough therapy designation granted as Company advances the PIONEER registrational program in optic neuropathies to create a potential market of $7B+ in the U.S. aloneMultiple milestones anticipated from late-stage portfolio including topline results from DIAMOND Phase 3 trials with OCS-01 eye drops in diabetic macular edema (DME) expected in Q2 2026 Riad Sherif, M.D., Chief Executive Officer, ...

January 8, 2026 1 EN
 PRESS RELEASE
Free
OCS OCULIS HOLDING ...

Oculis to Showcase Transformative Late-stage Pipeline in Neuro-ophthal...

Oculis to Showcase Transformative Late-stage Pipeline in Neuro-ophthalmology and Ophthalmology at the 2026 J.P. Morgan Healthcare Conference Breakthrough therapy designation granted as Company advances the PIONEER registrational program in optic neuropathies to create a potential market of $7B+ in the U.S. aloneMultiple milestones anticipated from late-stage portfolio including topline results from DIAMOND Phase 3 trials with OCS-01 eye drops in diabetic macular edema (DME) expected in Q2 2026 Riad Sherif, M.D., Chief Executive Officer, will present at the J.P. Morgan Healthcare Conference ...

January 8, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch